yes i take peptides · shopping companion

ARA-290 (Cibinetide)

Cibinetide

Category · For CognitionStatus · RUOCitations · 58

The verdict

Yes, but only for documented small-fiber neuropathy that hasn't responded to standard care — and only if you have a clinician willing to monitor before/after pain scores.

By source — cost, legality, risk

FDA-approved brand
Not available (trial-program supply only)
None — Phase 2, no FDA approval
No brand exists outside Araim trial program.
Compounded 503A (rare/investigational)
$200–$400/mo where available
Rare; investigational compound
Hard to source legally pre-approval; very few compounders engage.
RUO research-chemical site
$120–$250/mo
Sold for research only
Highest. Dominant off-label channel; identity and purity unverified.
Gray-market overseas raw
$85–$95/mo
Illegal to import for human use
Highest. Niche neuropathy use; small but live gray-channel.

Stop signals · abort if

rising hematocrit (supply identity concern)
new thrombotic symptoms (calf swelling, pleuritic chest pain
get evaluated)
allergic reaction

Sources · top 5 of 58

01Tracey KJ. Editorial. Molecular medicine (Cambridge, Mass.). 2013;19(1):333. PMID: 24178588.
02van Velzen M, et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert opinion on investigational drugs. 2014;23(4):541-50. PMID: 24555851.
03Zhang W, et al. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides. 2016;76:73-9. PMID: 26774587.
04Rendell MS. The time to develop treatments for diabetic neuropathy. Expert opinion on investigational drugs. 2021;30(2):119-130. PMID: 33423557.
05Al-Onaizi MA, et al. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity. 2022;99:363-382. PMID: 34343617.